Research tools
Biopsy articles covering tissue sampling, diagnosis, inflammation assessment, dysplasia surveillance, and IBD research findings. Research context emphasizes studies, trials, biomarkers, mechanisms, and emerging IBD science.
38 articles
A reusable transcriptomic atlas could let researchers compare new IBD biopsy datasets to a common reference, improving cross-study comparisons and helping separate inflammation from persistent disease-state biology that...
The study aims to clarify differences in visceral sensitivity and collect multiple biological samples that could help explain why some people with IBD have IBS-like symptoms. Findings could inform better symptom-targeted...
Predicting who will relapse after stopping anti-TNF drugs could help avoid unnecessary flares or unnecessary ongoing treatment. A biopsy-based transcriptomic test could be a useful decision tool if validated.
If validated, mucosal biomarkers like SPARC and SPP1 might help predict who will not respond to infliximab, potentially guiding treatment choices and avoiding ineffective therapy for some people with UC.
Understanding why some IBD ulcers fail to heal could help researchers develop better treatments or biomarkers to predict healing, which matters because mucosal healing reduces hospitalizations, surgeries, and cancer...
This trial investigates a new oral medication (PALI-2108) for moderate-to-severe ulcerative colitis and could expand treatment options if later trials show benefit and safety. The study focuses on clinical remission at...
Researchers are testing whether blocking three inflammation pathways at once can reduce tissue inflammation more than single drugs. If ex vivo results show stronger effects, it could guide development of multi-target...
The study aims to map the specific peptide targets of T cells driving organ inflammation in autoimmune diseases, which could guide development of antigen-specific, tolerogenic treatments relevant to Crohn's disease and...
Patients and clinicians struggle to predict relapse in ulcerative colitis because current endoscopic, histologic, and noninvasive biomarkers are imperfect. A tissue-based imaging and spatial-omics approach could identify...
This project could introduce a novel, microbiome-targeted oral therapy for Crohn’s disease if the Phase II trial confirms safety and clinical benefit; that matters because many patients need new options when current...
Knowing biomarkers that predict who will respond to IL23 p19 inhibitors could help people with IBD avoid trial-and-error therapy choices. Understanding whether increasing risankizumab dosing after loss of response...
A quantitative, biopsy-based measure of collagen architecture could help study intestinal fibrosis, which underlies stricture formation in Crohn’s disease. Feasibility data support further validation work that may lead...
Fibrosis and stricture formation are important complications in Crohn’s disease; a biopsy-based, quantitative way to measure collagen architecture could help research into fibrotic disease mechanisms and eventually...
People with stricturing Crohn’s disease currently lack effective medical treatments to prevent or reverse intestinal fibrosis; this trial explores a probiotic approach (and trehalose) aimed at stimulating autophagy, a...
Distinguishing UC from Crohn’s colitis can be challenging but affects long-term management and surveillance. A histologic feature—homogeneity versus heterogeneity of epithelial lesions across biopsies—might help improve...
This trial tests a new oral live biotherapeutic designed to affect inflammation and the gut microbiome in Crohn’s disease. Early‑phase safety and pharmacodynamic results could influence future development of...
The study shows that mucosal CD3+ T‑cell density is higher in dogs with an IBD-like condition than in healthy dogs, suggesting mucosal T‑cell infiltration is part of the disease but may not reflect how sick an individual...
People with Crohn's disease who develop symptomatic intestinal strictures currently often need endoscopic dilation or surgery. This trial tests an investigational oral drug (ontunisertib) aiming to improve...
Early-phase mechanistic trials test how a new drug affects disease biology and safety; results can help decide whether larger trials should follow.
The project aims to enable simultaneous RNA-level profiling of microbes and host cells from human biopsies, which could reveal early microbial and host gene-expression patterns linked to subclinical Crohn’s disease and...
Distinguishing IBD from gastrointestinal tuberculosis is challenging in regions where GITB is common; histologic markers like basal plasmacytosis and eosinophilia on mucosal biopsy could help guide diagnosis when...
An organoid platform that models epithelial injury and recovery could help researchers test treatments and biomarkers more precisely and at scale, accelerating work relevant to Crohn’s disease and other IBDs.
GI infections—especially CMV—were common in this study and much more frequent in acute severe UC than in remission, suggesting testing for infections can change diagnosis and management during severe flares.
Pouchitis is a common complication after IPAA and noninvasive tools to detect inflammation could make monitoring easier and less burdensome than repeated pouchoscopy. This trial tested whether intestinal ultrasound can...
AI models that combine CTE/MRE imaging with clinical and molecular data could improve objective classification of small-bowel Crohn's disease and help predict which patients are likely to respond to medical therapy...
Patients and clinicians may care because the study suggests contrast-enhanced CT can reliably detect and localize IBD, including transmural and small-bowel disease that biopsies miss, which could affect diagnostic...
Phase 1 platform studies like this one test safety and tolerability of new treatments for moderate-to-severe ulcerative colitis before larger trials. Findings from such early studies determine whether a drug moves...
Early-phase trials test safety and tolerability of new mechanisms; this study evaluates an anti–IL-18 antibody (aletekitug) which could represent a different therapeutic approach for people with moderate-to-severe UC if...
EEN is being evaluated as a non‑pharmacologic induction therapy in adults with active and complicated Crohn’s disease; results could inform whether EEN helps induce remission, improve nutrition, and impact inflammation...
If confirmed, an endocytoscopic appearance that corresponds to a specific miRNA and chemokine pattern could help clinicians assess mucosal inflammation during colonoscopy and prioritize biopsies or treatment decisions...
People with IBD may have a higher-than-expected rate of biopsy-confirmed celiac disease in this Northern Indian cohort, and standard anti-tTG blood tests can be falsely positive in IBD. Confirmatory duodenal biopsy is...
People with UC can develop severe neutrophilic skin complications like Sweet’s syndrome that may reflect active bowel inflammation even when recent tests suggested remission.
This trial tests etrasimod (an S1P receptor modulator) specifically in older adults with active ulcerative colitis — a group often underrepresented in IBD trials. Results could inform safety and short-term remission...
Granulomas are a classic histologic feature of Crohn’s disease, so patients and clinicians may wonder whether their presence predicts worse disease or different treatment needs. This review shows existing studies are...
CMV reactivation can worsen outcomes in active UC and influence treatment choices; clinicians and patients may benefit from additional, easy-to-measure markers that flag higher risk of tissue CMV and prompt targeted...
This NIH natural-history study is collecting clinical, immune, and genetic samples from people with Crohn’s disease and ulcerative colitis to better understand immune pathways and molecular causes of IBD. Those findings...
The atlas maps which genes and cell types are different in Crohn's disease, offering clues about why inflammation persists and pointing to specific immune pathways (like JAK/STAT) that are already drug targets. The...
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
